The 2 Minute Medicine® Podcast
The 2 Minute Medicine® Podcast- Episode 44
Jul 12, 2024
The podcast covers a new anti-CD38 antibody for immune thrombocytopenia, intestinal transplants, bird flu impacts on humans and animals, injuries in the USA Olympic trials, athletes' recovery from injuries, and risks of artificial sweeteners.
12:11
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- A novel anti-CD38 monoclonal antibody shows success in treating Immune Thrombocytopenia by targeting plasma cells.
- Intestinal transplants for mesenteric ischemia present challenges, but successful cases can have positive outcomes.
Deep dives
Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia
A novel anti-CD38 monoclonal antibody, CM313, showed promise in treating Immune Thrombocytopenia (ITP) by targeting plasma cells. In a phase 1-2 trial, 95% of patients achieved the primary efficacy outcome, with a median time to improved platelet levels within 1 week. Adverse events were mostly mild, with 64% of patients experiencing durable platelet response by 24 weeks. The therapy's success was attributed to reduced CD38 positive immune cells and plasma cells following treatment.
